Epidemiology and treatment of invasive fungal diseases in XXXX with @entity1582 : findings from a multicenter prospective study from China.

@entity1 @entity2380 @entity1582 @entity358 @entity3 @entity18111 @entity3028 @entity8201
UNASSIGNED: The aim of this study is to investigate the epidemiology, diagnosis, treatment and risk factors of @entity1582 @entity1 with @entity3 ( @entity3 ) in China. We analyzed @entity1582 ( @entity1582 ) @entity1 receiving chemotherapy in a prospective multicenter study. Basic characteristics, the diagnosis, and treatment of @entity3 were recorded. A total of 395 @entity1582 @entity1 were enrolled, who received a total of 443 chemotherapy courses. Among them, 17 IFDs were diagnosed during one chemotherapy course. Fourteen of these were possible @entity3 and 3 were probable @entity3 . Ten of the 14 @entity1 with possible @entity3 had @entity358 . Thirty eight (8.6  %) patients received antifungal prophylaxis, and 47.4  % of them were administered with @entity2380 . @entity1 who had a history of @entity3 or underwent a combined therapy with two antibiotics for over 7  days and with a history of @entity3028 or ductus venosus insertion were more likely to be treated with antifungal prophylaxis. All of first-line antifungal therapies were monotherapy. Eleven (84.6  %) cases were treated with @entity8201 . The median time of initial antifungal therapy was 8  days. The general condition of two @entity1 with probable @entity3 and 10 @entity1 (90.9  %) with possible @entity3 improved, while 1 @entity1 with possible @entity3 died. Multivariate analysis revealed that history of @entity3 is an independent risk factor of @entity3 . The present multicenter study suggests that the incidence of @entity3 per chemotherapy courses in @entity1582 @entity1 is 3.8  % and most @entity1 are labelled as having possible @entity3 . @entity2380 is the most common antifungal agent for prophylaxis and @entity18111 for therapeutic treatment. Previous @entity3 is a probable independent risk factor of @entity3 in @entity1582 @entity1 receiving chemotherapy.
